Tobias Zimmermann
Consultant / Senior Researcher
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (18)
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Aims We aimed to test the hypothesis if combining coronary artery calcium score (Ca-score) as a quantitative anatomical marker of coronary atherosclerosis with high-sensitivity cardiac troponin as a quantitative biochemical marker of myocardial injury provided incremental value in the detection of functionally relevant coronary artery disease (fCAD) and risk stratification. Methods and results Consecutive patients undergoing myocardial perfusion single-photon emission computed tomography (MPS) without prior CAD were enrolled. The diagnosis of fCAD was based on the presence of ischaemia on MPS and coronary angiography; fCAD was centrally adjudicated in the diagnostic and prognostic domain. Diagnostic accuracy was evaluated using the area under the receiver-operating characteristic curve (AUC). The composite of cardiovascular death and non-fatal acute myocardial infarction (AMI) within 730 days was the primary prognostic endpoint. Among 1715 patients eligible for the diagnostic analysis, 399 patients had fCAD. The combination of Ca-score and high-sensitivity cardiac troponin T (hs-cTnT) had good diagnostic accuracy for the diagnosis of fCAD (AUC 0.79, 95% confidence interval (CI) 0.77–0.81), but no incremental value compared with the Ca-score alone (AUC 0.79, 95% CI 0.77–0.81, P = 0.965). Similar results were observed using high-sensitivity cardiac troponin I (AUC 0.80, 95% CI 0.77–0.82) instead of hs-cTnT. Among 1709 patients (99.7%) with available follow-up, 59 patients (3.5%) suffered the composite primary prognostic endpoint (non-fatal AMI, n = 34; CV death, n = 28). Both Ca-score and hs-cTnT had independent prognostic value. Increased risk was restricted to patients with elevation in both markers. Conclusion The combination of the Ca-score with hs-cTnT increases the prognostic accuracy for future events but does not provide incremental value vs. the Ca-score alone for the diagnosis of fCAD. Study registration Clinical trial registration: NCT00470587.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Collaborators (16)
Mervyn Singer
University College London
Michael J Zellweger
MD/ Professor of Cardiology
University Hospital Basel
Johannes Tobias Neumann
University Heart and Vascular Center Hamburg
Sven Knecht
Technical Leader Electrophysiology
University Hospital Basel
Hamid MERDJI
Associate Professor of Intensive Care Medicine
University of Strasbourg
Simon Adrian Amacher
University Hospital Basel
Dimitrios Doudesis
BHF Principal Investigator | Senior Data Scientist
University of Edinburgh
Michael Christ
Head
Luzerner Kantonsspital
Caroline E. Gebhard
University Hospital Basel
Vera Regitz-Zagrosek
Director, Prof. dr. Dr
Charité - Universitätsmedizin Berlin
Michael Kunz
University Hospital Basel
Thomas Nestelberger
University Hospital Basel
Andreas Buser
Prof. Dr. med. , Head Transfusion Medicine
University Hospital Basel
Matthias Diebold
University Hospital Basel
Pedro Lopez Ayala
University Hospital Basel
Cass Li
University of Edinburgh
Make your next move.
Prepare your application
Review drafts before you send them.